506260 ANUHPHR

Anuh Pharma Share Price

₹194.90 +5.45 (2.88%)

23 Nov, 2024 23:15

SIP TrendupStart SIP in ANUHPHR

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 0.65%
  • Over 3 Month -7.23%
  • Over 6 Month -17.03%
  • Over 1 Year + 15.36%
SIP Lightning

Smart Investing Starts Here Start SIP with Anuh Pharma for Steady Growth!

Invest Now

Anuh Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Anuh Pharma Financials

Anuh Pharma Technicals

EMA & SMA

Current Price
₹194.90
+ 5.45 (2.88%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹195.18
  • 50 Day
  • ₹200.28
  • 100 Day
  • ₹206.28
  • 200 Day
  • ₹202.39

Resistance and Support

193.07 Pivot Speed
  • R3 205.53
  • R2 200.77
  • R1 197.83
  • S1 190.13
  • S2 185.37
  • S3 182.43

What's your outlook on Anuh Pharma?

You can only vote for once

Anuh Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-08 Quarterly Results
2024-08-09 Quarterly Results
2024-05-17 Audited Results & Final Dividend
2024-02-09 Quarterly Results
2023-11-10 Quarterly Results

Anuh Pharma F&O

Anuh Pharma Shareholding Pattern

No data available.

About Anuh Pharma

  • NSE Symbol
  • ANUHPHR
  • BSE Symbol
  • 506260
  • ISIN
  • INE489G01022

Similar Stocks to Anuh Pharma

Anuh Pharma FAQs

Anuh Pharma share price is ₹194 As on 23 November, 2024 | 23:01

The Market Cap of Anuh Pharma is ₹976.7 Cr As on 23 November, 2024 | 23:01

The P/E ratio of Anuh Pharma is 16.5 As on 23 November, 2024 | 23:01

The PB ratio of Anuh Pharma is 3.4 As on 23 November, 2024 | 23:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23